Juno Therapeutics (NASDAQ:JUNO) was downgraded by stock analysts at Citigroup from a “buy” rating to a “neutral” rating in a note issued to investors on Wednesday, The Fly reports.
JUNO has been the subject of several other reports. Maxim Group reiterated a “buy” rating and issued a $56.00 price objective on shares of Juno Therapeutics in a research report on Thursday, November 2nd. Wells Fargo & Co lowered Juno Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Tuesday, December 12th. Wedbush lowered Juno Therapeutics from an “outperform” rating to a “neutral” rating in a research report on Wednesday. Cowen restated a “buy” rating and set a $49.00 price target on shares of Juno Therapeutics in a research report on Friday, October 27th. Finally, Raymond James Financial restated a “buy” rating on shares of Juno Therapeutics in a research report on Monday, December 11th. Three investment analysts have rated the stock with a sell rating, ten have issued a hold rating and seven have given a buy rating to the company’s stock. Juno Therapeutics has a consensus rating of “Hold” and a consensus target price of $47.26.
Shares of Juno Therapeutics (JUNO) traded up $23.65 during trading on Wednesday, reaching $69.25. The company had a trading volume of 22,190,000 shares, compared to its average volume of 2,440,000. The stock has a market capitalization of $7,910.00, a price-to-earnings ratio of -20.43 and a beta of 2.32. Juno Therapeutics has a 52 week low of $18.90 and a 52 week high of $70.00. The company has a quick ratio of 4.77, a current ratio of 4.77 and a debt-to-equity ratio of 0.01.
In other news, Director Richard Klausner sold 36,000 shares of the stock in a transaction on Thursday, December 21st. The stock was sold at an average price of $44.76, for a total value of $1,611,360.00. Following the sale, the director now directly owns 744,392 shares in the company, valued at $33,318,985.92. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Robert Azelby sold 1,816 shares of the stock in a transaction on Monday, December 18th. The shares were sold at an average price of $44.96, for a total value of $81,647.36. Following the completion of the sale, the executive vice president now owns 70,832 shares in the company, valued at $3,184,606.72. The disclosure for this sale can be found here. Over the last quarter, insiders sold 65,956 shares of company stock worth $3,064,378. Insiders own 15.08% of the company’s stock.
Several hedge funds and other institutional investors have recently made changes to their positions in the company. The Manufacturers Life Insurance Company raised its stake in shares of Juno Therapeutics by 7.2% in the second quarter. The Manufacturers Life Insurance Company now owns 3,405 shares of the biopharmaceutical company’s stock valued at $102,000 after acquiring an additional 228 shares in the last quarter. Aperio Group LLC raised its stake in shares of Juno Therapeutics by 4.2% in the third quarter. Aperio Group LLC now owns 29,554 shares of the biopharmaceutical company’s stock valued at $1,326,000 after acquiring an additional 1,194 shares in the last quarter. SG Americas Securities LLC raised its stake in shares of Juno Therapeutics by 9.5% in the third quarter. SG Americas Securities LLC now owns 15,254 shares of the biopharmaceutical company’s stock valued at $684,000 after acquiring an additional 1,328 shares in the last quarter. Advisor Group Inc. raised its stake in shares of Juno Therapeutics by 141.1% in the third quarter. Advisor Group Inc. now owns 2,459 shares of the biopharmaceutical company’s stock valued at $109,000 after acquiring an additional 1,439 shares in the last quarter. Finally, Macquarie Group Ltd. raised its stake in shares of Juno Therapeutics by 17.5% in the third quarter. Macquarie Group Ltd. now owns 9,750 shares of the biopharmaceutical company’s stock valued at $437,000 after acquiring an additional 1,450 shares in the last quarter. Institutional investors and hedge funds own 69.94% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Juno Therapeutics (JUNO) Downgraded to Neutral at Citigroup” was originally published by American Market News and is owned by of American Market News. If you are accessing this story on another website, it was illegally copied and republished in violation of United States and international copyright laws. The correct version of this story can be viewed at https://www.americanbankingnews.com/2018/01/17/juno-therapeutics-juno-downgraded-to-neutral-at-citigroup.html.
About Juno Therapeutics
Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.
